Dexamethasone (Dex) produces an unpredictable adrenal suppressive response in CAH patients. Maintenance steroid therapy was stopped for 48h in 11 patients (14-21 yr) with 21-OH deficiency. Each then received 0.01 mglkg boluses of Dex I.V. and orally on consecutive days at 0900 h. Plasma 17P and Dex levels were measured every 10 min. for the first hour, then hourly for 24h on each occasion.
PHARMACODYNAMIC RESPONSE OF 170H-PROGESTERONE (17P) TO ACUTE DEXAMETHASONE IN CONGENITAL ADRENAL HYPERPLASIA (CAH).
Dexamethasone (Dex) produces an unpredictable adrenal suppressive response in CAH patients. Maintenance steroid therapy was stopped for 48h in 11 patients (14-21 yr) with 21-OH deficiency. Each then received 0.01 mglkg boluses of Dex I.V. and orally on consecutive days at 0900 h. Plasma 17P and Dex levels were measured every 10 min. for the first hour, then hourly for 24h on each occasion.
Dex elimination half Life (t-p Dex) was 2.18 -4.50h (mean 3.53).
Mean plasma 17P pre-I.V:~ex'(17~ max) was 331 nmolll (42-565); individual values were inversely proportional to adequacy of control on maintenance therapy. Both I.V. and oral Dex caused an immediate and exponential fall in 17P to produce complete cessation of adrenal 17P secretion followed by natural 1st order elimination f 17P from plasma. t~p 17P was 1.93 -2.93h (mean 2.55).
iatisfactory 17P level; (<30 nmolll) were achieved up to 13.2h (mean 8.2) after a Dex dose. 17P levels were maintained for a period (P) ranging from 16-2Oh (meen 18h) until a sharp rise at light. tip Dex did not correlate with P; the former value (mean 3.53h) predicts < 3 X Dex dose remaining after 18h. A single norning dex dose (0.01 mglkg) causes complete suppression of jaytime 17P values but when 17P increases again depends on 17Pmax at time of dose, tf B 17P and 17P circadian rhythm periodicity; the last 2 parameters are unique to each patient.
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LARGE SCALE PHYSICAL MAPPING OF THE REGION SUR-ROUNDING THE ADRENOLEUKODYSTROPHY GENE Adrenoleukodystrophy (ALD) is an X-linked genetic peroxisomal disorder in which phenotype may be strictly limited to Addison's disease. Though there is circumstantial evidence that the primary defect involves lignoceryl-CoA-synthetase, the precise gene involved has not yet been identified. Both ALD and redlgreen color blindness (CBD) have been mapped to the distal long arm of the X chromosome (Xq2-8). We have studied 13 French ALD kindreds and found visual pigment genes reorganization and/or deletion in 8 of 13 kindreds (60%) as opposed to the 8% expected. Such changes may reflect chromosomal events underlying both ALD and CBD genes. A physical map is clearly needed to understand the reorganization of this region in ALD patients and will constitute a first step to approach the ALD gene by "chromosome walking" or "jumping". High molecular weight genomic DNA digested with a number of restriction enzymes that cut infrequently was separated by pulse field gel electrophoresis and hybridized to cDNA and anonymous genomic probes that derive from Xq2-8. Preliminary results suggest that ALD gene lies between coagulation Factor VIII and CBD genes at a distance of less than 150 kb from CBD. 9 out of 12 patients showed a change of normal molecular organisation: In 2 siblings and 3 other unrelated patients, we found a normal Taq I pattern but, at the same time,the loss of the A genc specific Hind I11 frafpent. Another patient showed an increased 1 gene signal in the Taq I digest,whereas in the Eco R I digest the A gene signal was increased. Two liLA identical siblings, one wit) mild, the other with severe CAII, both surprisingly showed homozygous loss of the 3.7 kb Taq I fragment. However, Eco R I digest revealed that the B gene specific recognition sites were preserv. ed.The same occured in another unrelated patient. We infer frequent exchange between the 2 neighbouring 21-OHase A and B genes by either unequal crossing over or gene conversion resulting in hybrid genes that carry A-as well as B gene specific recognition sites in the gene or its' surrounding districts. I1 were treated by IM injections every 4 weeks of the LH-RH agonist triptorelin (Decapeptyl microcapsules, 60 ug/kg body weight). After 6 months basal and peak levels increased respectively to 1.1 + 0.12 and 2.0 + 0.20 (p < 0.001 relative to pretreatment values). The increment (0.84 + 0.11) was significan tly higher than in groups I, untreated I1 and 111. These data suggest that : l-ovarian secretion might exert a suppressive effect on the release of F-TSH-A ; 2-long term LH-RH agonist adm nistration might increase a-subunit secretion not only by the gonadotroph cells, but also by the thyreotroph cells, provided i direct effect of TRH on the gonadotrophs can be precluded.
